王兆天,郭鹏威

糖尿病肾病（DN）是糖尿病最主要且严重的微血管并发症，其核心病理在于高血糖、氧化应激与炎症趋化因子等多种因素的共同作用。这些因素会触发一系列反应，包括损伤血管内皮细胞、增加微血管通透性，并促使炎症细胞向肾脏病变部位募集，最终共同推动了DN的发生与进展。研究表明，长链非编码RNA肺腺癌转移相关转录本1（lncRNA-MALAT1）与多种高糖状态下的炎症并发症反应密切相关，包括糖尿病引起的并发症如糖尿病肾脏病变，其通过调节下游相关靶基因的表达或介导相关信号通路的活性在DN的疾病进展中起着关键作用。本文对lncRNA-MALAT1在糖尿病肾病治疗中的研究进展展开综述，为糖尿病肾病临床治疗提供新思路及理论依据。

糖尿病肾病；长链非编码RNA；肺腺癌转移相关转录本1；研究进展

[1] Zare S M,Zare S F,Mehrparvar A H,et al.Association between noise exposure and diabetes:A systematic review and meta-analysis[J]. Environ Res,2018,166:647-657. [2] 陈俊安,蓝红波,梁江燕,等.2型糖尿病患者血糖水平､Hp感染对糖尿病肾病发生率影响及与肾脏损伤程度的相关性分析[J].糖尿病新世界,2023,26(13):1-4. [3] Tavafi M.Diabetic nephropathy and antioxidants[J].J Nephropathol,2013,2(1):20-27. [4] Donate-Correa J,Luis-Rodriguez D,Martin-Nunez E,et al.Inflammatory Targets in Diabetic Nephropathy[J].J Clin Med,2020,9(2). [5] Thallas-Bonke V,Thorpe S R,Coughlan M T,et al.Inhibition of NADPH oxidase prevents advanced glycation end product-mediated damage in diabetic nephropathy through a protein kinase C-alpha-dependent pathway[J].Diabetes,2008,57(2):460-469. [6] Kopel J,Pena-Hernandez C,Nugent K.Evolving spectrum of diabetic nephropathy[J].World J Diabetes,2019,10(5):269-279. [7] Duni A,Liakopoulos V,Roumeliotis S,et al.Oxidative Stress in the Pathogenesis and Evolution of Chronic Kidney Disease:Untangling Ariadne's Thread[J].Int J Mol Sci,2019,20(15). [8] Khazim K,Gorin Y,Cavaglieri R C,et al.The antioxidant silybin prevents high glucose-induced oxidative stress and podocyte injury in vitro and in vivo[J].Am J Physiol Renal Physiol,2013,305(5):F691-F700. [9] Brownlee M.The pathobiology of diabetic complications:a unifying mechanism[J].Diabetes,2005,54(6):1615-1625. [10] Forbes J M,Coughlan M T,Cooper M E.Oxidative stress as a major culprit in kidney disease in diabetes[J].Diabetes,2008, 57(6):1446-1454. [11] Wong C K,Ho A W,Tong P C,et al.Aberrant activation profile of cytokines and mitogen-activated protein kinases in type 2 diabetic patients with nephropathy[J].Clin Exp Immunol,2007,149(1):123-131. [12] Lim A K,Tesch G H.Inflammation in diabetic nephropathy[J].Mediators Inflamm,2012,2012:146154. [13] Pickup J C,Chusney G D,Thomas S M,et al.Plasma interleukin-6,tumour necrosis factor alpha and blood cytokine production in type 2 diabetes[J].Life Sci,2000,67(3):291-300. [14] Zhuang L,Wang Z,Hu X,et al.CircHIPK3 Alleviates High Glucose Toxicity to Human Renal Tubular Epithelial HK-2 Cells Through Regulation of miR-326/miR-487a-3p/SIRT1[J].Diabetes Metab Syndr Obes,2021,14:729-740. [15] 徐玉清,邢纪心,梅小斌.炎症及抗炎治疗在糖尿病肾病中的研究进展[J].海军军医大学学报,2024:1-7. [16] Ji P,Diederichs S,Wang W,et al.MALAT-1,a novel noncoding RNA,and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer[J].Oncogene,2003,22(39):8031-8041. [17] Arun G,Diermeier S,Akerman M,et al.Differentiation of mammary tumors and reduction in metastasis upon Malat1 lncRNA loss[J].Genes Dev,2016,30(1):34-51. [18] Michalik K M,You X,Manavski Y,et al.Long noncoding RNA MALAT1 regulates endothelial cell function and vessel growth[J].Circ Res,2014,114(9):1389-1397. [19] Uchida S,Dimmeler S.Long noncoding RNAs in cardiovascular diseases[J].Circ Res,2015,116(4):737-750. [20] Vausort M,Wagner D R,Devaux Y.Long noncoding RNAs in patients with acute myocardial infarction[J].Circ Res,2014,115(7):668-677. [21] Puthanveetil P,Chen S,Feng B,et al.Long non-coding RNA MALAT1 regulates hyperglycaemia induced inflammatory process in the endothelial cells[J].J Cell Mol Med,2015,19(6):1418-1425. [22] Cao D W,Liu M M,Duan R,et al.The lncRNA Malat1 functions as a ceRNA to contribute to berberine-mediated inhibition of HMGB1 by sponging miR-181c-5p in poststroke inflammation[J].Acta Pharmacol Sin,2020,41(1):22-33. [23] Feng L L,Xin W N,Tian X L.MALAT1 modulates miR-146's protection of microvascular endothelial cells against LPS-induced NF-kappaB activation and inflammatory injury[J].Innate Immun,2019,25(7):433-443. [24] Huang H,Zhang G,Ge Z.lncRNA MALAT1 Promotes Renal Fibrosis in Diabetic Nephropathy by Targeting the miR-2355-3p/IL6ST Axis[J].Front Pharmacol,2021,12:647650. [25] Liu J Y,Yao J,Li X M,et al.Pathogenic role of lncRNA-MALAT1 in endothelial cell dysfunction in diabetes mellitus[J].Cell Death Dis,2014,5(10):e1506. [26] Gupta R A,Shah N,Wang K C,et al.Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis[J]. Nature,2010,464(7291):1071-1076. [27] 赵焕焕,刘东伟,潘少康,等.糖尿病肾病中长链非编码RNA介导的调控网络[J].中华肾脏病杂志,2020,36(12):970-976. [28] Gutschner T,Hammerle M,Diederichs S.MALAT1--a paradigm for long noncoding RNA function in cancer[J].J Mol Med(Berl), 2013,91(7):791-801. [29] Mayr F,Heinemann U.Mechanisms of Lin28-mediated miRNA and mRNA regulation--a structural and functional perspective[J].Int J Mol Sci,2013,14(8):16532-16553. [30] Tsialikas J,Romer-Seibert J.LIN28:roles and regulation in development and beyond[J].Development,2015,142(14):2397-2404. [31] Ma F,Zhou Z,Li N,et al.Lin28a promotes self-renewal and proliferation of dairy goat spermatogonial stem cells(SSCs)through regulation of mTOR and PI3K/AKT[J].Sci Rep,2016,6:38805. [32] Yang Q,Wu F R,Wang J N,et al.Nox4 in renal diseases:An update[J].Free Radic Biol Med,2018,124:466-472. [33] Njeim R,Farhat T,Alkhansa S,et al.Role of the Nox4/AMPK/mTOR signaling axe in adipose inflammation-induced kidney injury[J]. Clin Sci(Lond),2020,134(4):403-417. [34] Song P,Chen Y,Liu Z,et al.LncRNA MALAT1 Aggravates Renal Tubular Injury via Activating LIN28A and the Nox4/AMPK/mTOR Signaling Axis in Diabetic Nephropathy[J].Front Endocrinol(Lausanne),2022,13:895360. [35] 杜华,张宁,李玎玎,等.益肾颗粒通过调控LncRNA MALAT1和mTOR介导的自噬改善糖尿病肾病机制研究[J].中华中医药杂志,2020,35(5):2338-2343. [36] 贺绍林,朱菡.LncRNA MALAT1对狼疮性肾炎小鼠肾小球系膜细胞增殖､凋亡､炎症反应的影响[J].医学研究与战创伤救治,2024, 37(10):1021-1026.

点击下载PDF